<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693093</url>
  </required_header>
  <id_info>
    <org_study_id>NI03-001</org_study_id>
    <nct_id>NCT02693093</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Study Evaluating Efficacy and Safety of NI-03</brief_title>
  <acronym>Tactic</acronym>
  <official_title>A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangen Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangen Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of NI-03.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the Single-Dose Phase is to assess the pharmacokinetics (PK) and&#xD;
      safety of single doses of NI-03 when administered at doses of 100 mg, 200 mg or 300 mg to&#xD;
      subjects with chronic pancreatitis.&#xD;
&#xD;
      The primary objective of the Double-Blind Phase of the study is to determine the efficacy, PK&#xD;
      and safety of three doses of NI-03 (100 mg, 200 mg and 300 mg) as compared to placebo when&#xD;
      administered three times daily (TID) for 28 consecutive days in subjects with chronic&#xD;
      pancreatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose</time_frame>
    <description>Pharmacokinetic (PK) parameters such as Maximum concentration (Cmax), time to maximum concentration (Tmax), minimum concentration(Cmin), area under the curve (AUC), half-life (t1/2), apparent clearance (CL/F), and apparent volume of distribution (Vz/F) are assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Safety and Tolerability - Treatment Emergent Adverse Events (TEAE) via CTCAE v4.0</measure>
    <time_frame>through 7 days post-dose</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 - Safety and Tolerability - Laboratory test results</measure>
    <time_frame>through 7 days post-dose</time_frame>
    <description>Laboratory test results will be graded and summarized based on CTCAE v4.03. and by shifts in results before and after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Efficacy Analysis - average daily worst pain intensity score</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA -area under the curve (AUC)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA - Maximum concentration (Cmax)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA - time to maximum plasma concentration (tmax)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA - apparent clearance (CL/F)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA - plasma terminal half-life (t1/2)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 - To determine the pharmacokinetic profile for FOY251 and GBA - apparent volume of distribution (Vz/F)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Efficacy Analysis - Change from baseline in least pain score</measure>
    <time_frame>change from baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Efficacy Analysis - Change from baseline in average pain score</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Efficacy Analysis - Change from baseline in current pain score</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Efficacy Analysis - Change from baseline in average morphine-equivalent daily opioid daily dose</measure>
    <time_frame>4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Efficacy Analysis - Change from baseline in quality of life</measure>
    <time_frame>change from baseline to Week 4</time_frame>
    <description>assessed using the pain interference aspects of the Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Safety and Tolerability - Treatment Emergent Adverse Events (TEAE) via CTCAE v4.0</measure>
    <time_frame>Through day 57 (End of Study Visit)</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - Safety and tolerability - Laboratory Test Results</measure>
    <time_frame>Through day 57 (End of Study Visit)</time_frame>
    <description>Laboratory test results will be graded and summarized based on CTCAE v4.03. and by shifts in results before and after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA -area under the curve (AUC)</measure>
    <time_frame>Days 1 and 29, and at 0.25, 0.5, 1, 2 and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA - Maximum concentration (Cmax)</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 1, 2, 4 and 8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA - time to maximum plasma concentration (tmax)</measure>
    <time_frame>Days 1 and 29, and at 0.25, 0.5, 1, 2 and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA - plasma terminal half-life (t1/2)</measure>
    <time_frame>Days 1 and 29, and at 0.25, 0.5, 1, 2 and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA - apparent clearance (CL/F)</measure>
    <time_frame>Days 1 and 29, and at 0.25, 0.5, 1, 2 and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2 - To determine the pharmacokinetic profile for FOY251 and GBA - apparent volume of distribution (Vz/F)</measure>
    <time_frame>Days 1 and 29, and at 0.25, 0.5, 1, 2 and 4 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TID Day for 28 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg NI-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TID Day for 28 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg NI-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TID Day for 28 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg NI-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TID Day for 28 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NI-03</intervention_name>
    <arm_group_label>100 mg NI-03</arm_group_label>
    <arm_group_label>200 mg NI-03</arm_group_label>
    <arm_group_label>300 mg NI-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in this study, subjects must meet all of the following&#xD;
        criteria at Screening:&#xD;
&#xD;
          1. Males and females aged 18 to 85 years, inclusive, at the time of consent&#xD;
&#xD;
          2. Ability to communicate effectively with clinic site staff, ability and willingness to&#xD;
             comply with the study schedule, restrictions, and requirements&#xD;
&#xD;
          3. Institutional Review Board (IRB)-approved written informed consent&#xD;
&#xD;
          4. Diagnosis of chronic pancreatitis&#xD;
&#xD;
          5. Baseline average daily worst pain score must be a minimum of 4 using the Numeric&#xD;
             Rating Scale (NRS) during the 7-day run-in period&#xD;
&#xD;
          6. Patients on a non-opioid analgesic regimen that is expected to remain stable during&#xD;
             the study period, or an opioid regimen with a morphine-equivalent dose not more than&#xD;
             100 mg daily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in this study, subjects must not meet any of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Any other clinically significant medical condition&#xD;
&#xD;
          2. Treatment with any investigational product within 14 days of Day 1 (or 5 drug&#xD;
             half-lives if 5 drug half-lives are expected to exceed 14 days) of Day -7&#xD;
&#xD;
          3. Major abdominal surgery within 90 days of Day 1&#xD;
&#xD;
          4. History or presence of clinically significant cardiovascular disease&#xD;
&#xD;
          5. History of any cancer, except non-melanoma skin cancer, within 5 years of study&#xD;
             enrollment,&#xD;
&#xD;
          6. History of endoscopic intervention within the previous 3 months or presence of a&#xD;
             pancreatic duct stent&#xD;
&#xD;
          7. History of illicit drug abuse (i.e. use of any 'illegal' drugs within 6 months)&#xD;
&#xD;
          8. Active heavy alcohol use (defined as more than 2 alcoholic drinks per day or 14&#xD;
             alcoholic drinks per week)&#xD;
&#xD;
          9. Inadequate venous access&#xD;
&#xD;
         10. Significant blood loss, donation of â‰¥450 mL of blood, or blood or blood product&#xD;
             transfusion within 7 days of Day 1&#xD;
&#xD;
         11. History or presence of hepatitis B (surface antigen positivity), active hepatitis C or&#xD;
             human immunodeficiency virus (HIV) antibody&#xD;
&#xD;
         12. Active infection within 30 days of Day 1&#xD;
&#xD;
         13. Pregnant, planning to become pregnant or breast feeding&#xD;
&#xD;
         14. Positive urine or serum pregnancy test result at Screening or on Day 1&#xD;
&#xD;
         15. Active major psychiatric illness requiring a change in treatment within 3 months that&#xD;
             would confound pain assessments&#xD;
&#xD;
         16. History of seizures within the last 12 months&#xD;
&#xD;
         17. Current use of anticonvulsants, antipsychotics, systemic steroids and,&#xD;
             immunosuppressant therapy. *Use of gabapentin, pregabalin and benzodiazepines as&#xD;
             treatment for chronic pancreatitis pain are allowed.&#xD;
&#xD;
         18. Presence of generalized pain syndrome apart from chronic pancreatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California, Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado-Div of Gastroenterology and Hepatology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Division of Gastroenterology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University - Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University (OSU) - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wisconsin Center for Advanced Research, a division of GI Associates LLC</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Research Centre Institute of Cytology and Genetics</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academu, Dep of Therapy of Adv. Training</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Department of Hospital Therapy</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #40</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Polyclinic #4</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University &quot;Reaviz&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomsk Regional Clinical Hospital</name>
      <address>
        <city>Tomsk</city>
        <zip>634063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Gastroenterology</name>
      <address>
        <city>Dnipro</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central city Clinical Hospital, Therapeutic Department #2</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malaya Therapy National Institute</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Policlinic #9</name>
      <address>
        <city>Kharkiv</city>
        <zip>61172</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Named After Tropins, Therapy Department #1</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OK Clinic</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Consilium Medical&quot;</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Care Hospital, #1 Therapeutic Department</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital, Department of General Surgery</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st City Clinical Hospital, Therapeutic Department</name>
      <address>
        <city>Poltava</city>
        <zip>36038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1, Gastroenterology Department</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Diaservis</name>
      <address>
        <city>Zaporizhia</city>
        <zip>69076</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

